News stories about Eagle Pharmaceuticals (NASDAQ:EGRX) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 46.2385899761008 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

NASDAQ:EGRX traded down $0.06 during mid-day trading on Friday, reaching $66.66. The stock had a trading volume of 152,572 shares, compared to its average volume of 197,392. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 19.78 and a beta of 1.31. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.22 and a quick ratio of 4.09. Eagle Pharmaceuticals has a 12 month low of $48.84 and a 12 month high of $85.66.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.80 by $0.15. The business had revenue of $59.30 million for the quarter, compared to analysts’ expectations of $51.78 million. Eagle Pharmaceuticals had a net margin of 13.81% and a return on equity of 19.71%. analysts anticipate that Eagle Pharmaceuticals will post 2.15 EPS for the current fiscal year.

A number of equities research analysts have recently weighed in on the stock. Mizuho upgraded shares of Eagle Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research report on Monday, June 11th. Piper Jaffray Companies set a $88.00 price target on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 7th. Royal Bank of Canada set a $84.00 price target on shares of Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 8th. BidaskClub downgraded shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 25th. Finally, TheStreet upgraded shares of Eagle Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Thursday, August 9th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Eagle Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $86.67.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Read More: What is a Tariff?

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.